Trials / Completed
CompletedNCT01754766
AGN-229666 for the Treatment of Allergic Conjunctivitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-229666 | One drop of AGN-229666 into each eye on Day 1 and Day 15. |
| OTHER | vehicle of AGN-229666 | One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15. |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2013-01-01
- Completion
- 2013-02-01
- First posted
- 2012-12-21
- Last updated
- 2014-02-04
- Results posted
- 2014-02-04
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01754766. Inclusion in this directory is not an endorsement.